Charles Schwab Investment Management Inc Arrowhead Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,006,935 shares of ARWR stock, worth $19.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,006,935

Previous 994,361 1.26%

Holding current value

$19.7 Million

Previous $25.8 Million 24.57%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$19.36 - $29.54 $243,432 - $371,435	12,574 Added 1.26%	1,006,935 $19.5 Million
Q2 2024 Aug 12, 2024	BUY	$21.87 - $28.24 $231,953 - $299,513	10,606 Added 1.08%	994,361 $25.8 Million
Q1 2024 May 08, 2024	BUY	$27.21 - $39.48 $3.75 Million - $5.44 Million	137,776 Added 16.29%	983,755 $28.1 Million
Q4 2023 Feb 06, 2024	BUY	$21.2 - $31.03 $21,072 - $30,843	994 Added 0.12%	845,979 $25.9 Million
Q3 2023 Nov 08, 2023	SELL	$26.2 - $36.08 $7.86 Million - $10.8 Million	-300,074 Reduced 26.21%	844,985 $22.7 Million
Q2 2023 Aug 09, 2023	SELL	$25.16 - $41.38 $314,902 - $517,912	-12,516 Reduced 1.08%	1,145,059 $40.8 Million
Q1 2023 May 11, 2023	BUY	$23.68 - $38.51 $453,045 - $736,773	19,132 Added 1.68%	1,157,575 $29.4 Million
Q4 2022 Feb 13, 2023	BUY	$28.0 - $40.56 $966,000 - $1.4 Million	34,500 Added 3.13%	1,138,443 $46.2 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $742,379 - $1.21 Million	25,055 Added 2.32%	1,103,943 $36.5 Million
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $189,944 - $345,919	-6,835 Reduced 0.63%	1,078,888 $38 Million
Q1 2022 May 13, 2022	BUY	$39.62 - $69.97 $1.42 Million - $2.51 Million	35,829 Added 3.41%	1,085,723 $49.9 Million
Q4 2021 Feb 11, 2022	BUY	$58.09 - $82.51 $1.11 Million - $1.58 Million	19,141 Added 1.86%	1,049,894 $69.6 Million
Q3 2021 Nov 16, 2021	BUY	$58.38 - $84.96 $1.41 Million - $2.05 Million	24,108 Added 2.39%	1,030,753 $64.4 Million
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $2.88 Million - $4.18 Million	46,298 Added 4.82%	1,006,645 $83.4 Million
Q1 2021 May 17, 2021	BUY	$61.35 - $90.47 $2.02 Million - $2.97 Million	32,852 Added 3.54%	960,347 $63.7 Million
Q4 2020 Feb 16, 2021	BUY	$43.82 - $85.37 $559,931 - $1.09 Million	12,778 Added 1.4%	927,495 $71.2 Million
Q3 2020 Nov 13, 2020	BUY	$33.21 - $51.27 $6.15 Million - $9.5 Million	185,209 Added 25.39%	914,717 $39.4 Million
Q2 2020 Aug 14, 2020	BUY	$26.12 - $43.27 $691,709 - $1.15 Million	26,482 Added 3.77%	729,508 $31.5 Million
Q1 2020 May 15, 2020	BUY	$20.56 - $63.12 $1.52 Million - $4.67 Million	73,965 Added 11.76%	703,026 $20.2 Million
Q4 2019 Feb 07, 2020	BUY	$28.14 - $73.01 $695,029 - $1.8 Million	24,699 Added 4.09%	629,061 $39.9 Million
Q3 2019 Nov 08, 2019	BUY	$26.26 - $34.86 $231,324 - $307,081	8,809 Added 1.48%	604,362 $17 Million
Q2 2019 Aug 09, 2019	SELL	$17.43 - $28.82 $477,076 - $788,832	-27,371 Reduced 4.39%	595,553 $15.8 Million
Q1 2019 May 14, 2019	BUY	$12.05 - $20.18 $1.7 Million - $2.85 Million	141,181 Added 29.31%	622,924 $11.4 Million
Q4 2018 Feb 14, 2019	BUY	$10.74 - $19.7 $7,270 - $13,336	677 Added 0.14%	481,743 $5.98 Million
Q3 2018 Nov 13, 2018	BUY	$14.0 - $20.3 $324,450 - $470,452	23,175 Added 5.06%	481,066 $9.22 Million
Q2 2018 Aug 08, 2018	BUY	$6.37 - $14.02 $1.18 Million - $2.59 Million	184,849 Added 67.7%	457,891 $6.23 Million
Q1 2018 May 07, 2018	BUY	$3.72 - $7.64 $322,378 - $662,090	86,661 Added 46.5%	273,042 $1.97 Million
Q4 2017 Jan 17, 2018	BUY	$3.14 - $4.5 $47,514 - $68,094	15,132 Added 8.84%	186,381 $686,000
Q3 2017 Nov 13, 2017	BUY	$1.69 - $4.33 $289,410 - $741,508	171,249	171,249 $742,000

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.07B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Arrowhead Pharmaceuticals, Inc. Transaction History